Posted in 2017 CPhI North America Show Daily on May 16
PharmaBlock Sciences (Nanjing), Inc., a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process, has entered a new Commercial Supply Agreement for Drug Substance Starting Materials with Agios Pharmaceuticals, Inc., Cambridge, Massachusetts, a leader in the fields of cancer metabolism and rare genetic disorders of metabolism,as part of the commercial launch readiness.
Under this agreement, PharmaBlock will continuously provide Agios with drug substance starting materials and intermediatesfor commercial production.PharmaBlock and Agios have been involved in a long-term collaboration, from synthesis of lab-scale building blocks to bulk manufacturing of RSMs, as Agios’ drug R&D project moves on to later developmentstages. “We are pleased to have PharmaBlock as our strategic partner. With their capabilities in medicinal synthesis, process R&D, and manufacturing, we have collaborated from research to development to commercial.” said Ms. Wendy Xia, Director of Commercial Supplies at Agios, “It is an exciting story that we both experience the ‘scale-up’ together, and enter this commercial partnership eventually.”
"The Commercial Supply Agreement further strengthens our already productive relationship with Agios, one of our most valued customers for many years. It is our honor to be a part of Agios’ life-saving drug R&D projects and witness every milestone they have achieved along the way. We will continue to deliver our firm commitment to quality and custom satisfaction.” said Dr. Haijun Dong, Chief Executive Officer of PharmaBlock.